We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
Cap. Flow
-$160M
Cap. Flow %
-10.45%
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$13.5M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$11.9M
3
ESPR
Esperion Therapeutics
ESPR
+$4.02M
4
AIXC
AIxCrypto Holdings Inc
AIXC
+$2.59M
5
HURA
TuHURA Biosciences
HURA
+$2.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$59.2M
2
UTHR icon
United Therapeutics
UTHR
+$6.78M
3
TSRO
TESARO, Inc.
TSRO
+$5.95M
4
KITE
Kite Pharma, Inc.
KITE
+$4.37M
5
SPNC
Spectranetics Corp
SPNC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 7.34%
2 Technology 0.16%
3 Materials 0.11%
4 Consumer Staples 0.04%
5 Consumer Discretionary 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPL
226
PUT
DELISTED
Great Panther Mining Limited
GPL
– –
-208
Closed -$266K
CERN
227
CALL
DELISTED
Cerner Corp
CERN
– –
-1,400
Closed -$9.31M
DRNA
228
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-190,000
Closed -$602K
ALXN
229
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-800
Closed -$9.73M
ALXN
230
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-550
Closed -$6.69M
STML
231
PUT
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-451
Closed -$415K
NUROW
232
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
– –
-6,502
Closed -$7K
IDXG
233
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
– –
-52,982
Closed -$476K
MDCO
234
DELISTED
Medicines Co
MDCO
– –
-11,764
Closed -$434K
MDCO
235
PUT
DELISTED
Medicines Co
MDCO
– –
-127
Closed -$483K
MTFBW
236
DELISTED
Motif Bio plc Warrants to Purchase ADRs
MTFBW
– –
-141,334
Closed -$256K
ARRY
237
CALL
DELISTED
Array Biopharma Inc
ARRY
– –
-398
Closed -$333K
ARRY
238
DELISTED
Array Biopharma Inc
ARRY
– –
-155,757
Closed -$1.3M
ARRY
239
PUT
DELISTED
Array Biopharma Inc
ARRY
– –
-2,500
Closed -$2.09M
ADYX
240
DELISTED
Adynxx Inc
ADYX
– –
-17,857
Closed -$396K
SCMP
241
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-33,200
Closed -$349K
RXDX
242
CALL
DELISTED
Ignyta, Inc.
RXDX
– –
-164
Closed -$170K
CBMXW
243
DELISTED
CombiMatrix Corporation Warrant
CBMXW
– –
-545,309
Closed -$731K
KITE
244
DELISTED
Kite Pharma, Inc.
KITE
– –
-31,384
Closed -$4.37M
SPNC
245
DELISTED
Spectranetics Corp
SPNC
– –
-90,715
Closed -$3.48M
SPNC
246
PUT
DELISTED
Spectranetics Corp
SPNC
– –
-1,191
Closed -$4.57M
WINT
247
DELISTED
Windtree Therapeutics Inc
WINT
– –
-345,712
Closed -$112K
PARN
248
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
– –
-170,000
Closed -$143K
LJPC
249
CALL
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-346
Closed -$19K
AIM
250
AIM ImmunoTech
AIM
$6.54M
– –
-214
Closed -$472K
6 7 8 9
10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2017 Portfolio in Review

As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.

Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.

  • Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
  • Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
  • Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
  • Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
  • Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
  • Sabby Management opened 32 new positions and closed 82 in Q3 2017.
  • Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.